Published in Cancer Weekly, November 20th, 1995
The study researchers have injected the first patients ever with a p53/adenoviral gene therapy product for the treatment of non-resectable and resectable head and neck cancer and non-small cell lung cancer (NSCLC).
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.